Intellia Takes Its CRISPR HAE Fix to the FDA

Intellia has begun a rolling FDA BLA submission for lonvo-z after Phase 3 success, targeting a potential H1 2027 launch

22 Jun 2026

Intellia Therapeutics has begun a rolling submission to the US Food and Drug Administration for lonvo-z, its CRISPR-based therapy for hereditary angioedema, a rare condition causing severe and unpredictable swelling attacks. The decision follows positive results from the Phase 3 HAELO trial, which met its primary and key secondary endpoints.

Hereditary angioedema affects a small number of patients globally, many of whom rely on repeated preventive injections or infusions. Lonvo-z would be administered once, using CRISPR gene-editing technology delivered directly into the body. This approach, known as in vivo editing, differs from earlier methods that required cells to be modified outside a patient before reinfusion.

Rolling submissions permit companies to send completed sections of a regulatory application as they become ready, rather than waiting to file everything at once. Intellia expects to complete the full BLA package in the second half of 2026. FDA approval, if granted, could enable a commercial launch in the first half of 2027.

Should that timeline hold, Intellia would be the first company to bring an in vivo CRISPR therapy to patients in the United States, a distinction that carries weight beyond the hereditary angioedema market. Gene editing companies and their investors have long pointed to a regulatory first approval as the moment that would confirm the platform's clinical viability across a broader set of genetic diseases.

The path still depends on FDA review, and no approval is guaranteed. What the filing does confirm is that the HAELO data were strong enough for Intellia to begin formal engagement with regulators, a substantive step in an industry where most candidates do not reach this stage.